Solid nano-medicine and preparing method thereof

A technology of nano-medicine and medicine, which is applied in the direction of nano-medicine, nanotechnology, nanotechnology, etc., and can solve problems that do not meet the requirements of drug safety and industrial production.

Inactive Publication Date: 2009-07-29
刘 云清 +3
View PDF4 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most of them do not meet the requirements of drug safety and industrial production, and there have been no clinical and marketing reports so far.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Solid nano-medicine and preparing method thereof
  • Solid nano-medicine and preparing method thereof
  • Solid nano-medicine and preparing method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0087] Embodiment 1. Exemplary raw material formula

[0088] 1. Paclitaxel for injection Specification: 30mg / 2.5g

[0089] Matrix formula: Hydroxypropyl Beta Cyclodextrin 60 Phospholipids 8 Tween 80 9 The main parameters: Drug loading% 1.2

[0090] 2. Artemether for injection Specification: 60mg / 2.2g

[0091] Matrix formula: Hydroxypropyl Beta Cyclodextrin 31.5 Phospholipids 3 Tween 80 1.5 The main parameters: Drug loading% 2.7

[0092] 3. Dihydroartemisinin for injection Specification: 40mg / 1.5g

[0093] Matrix formula: Hydroxypropyl Beta Cyclodextrin 31.5 Phospholipids 3 Tween 80 3 The main parameters: Drug loading% 2.7

[0094] 4. Busulfan Specification: 2mg

[0095] Matrix formula: Hydroxypropyl Beta Cyclodextrin 17 Phospholipids 1.7 Tween 80 0.75 The main parameters: Drug loading% 5.1

[0096] 5. Nimodipin...

Embodiment 2

[0113] Preparation of paclitaxel for injection

[0114] In the preparation, the materials used are: hydroxypropyl beta cyclodextrin (for injection) Hydroxypropy-β-Cyclodextrin for Injection; soybean lecithin (for injection) Soya Phospholide for Injection; auxiliary agent polysorbate 80 Polysorbate-80 (Tween80); Povidone K 30 , Polydone K 30 or K 15 (PVP K 30 or K 15 ); and small molecule dextran, etc.

[0115] The formula for preparing paclitaxel for injection (nanoparticles) 30mg / 2.5g (branch) is:

[0116]

[0117] According to routine determination of the drug loading % of the present invention: 1.19.

[0118]Adjusting the formula to change the ratio of the matrix and the auxiliary agent can affect the solubility of the drug and control the particle size of the particles within a certain range to meet the requirements of the drug.

[0119] The matrix (carrier) and auxiliary agents in the formula are physiologically compatible, safe and easy to purchase. Wherein, p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

A method of preparing low water-soluble medicine into solid nanometer pharmaceutical formulation is disclosed. According to the characters of molecular aggregates such as supramolecular chemical micelles and vesicles, the formulation, which based on the hydroxypropyl-beta-cyclodextrin and phospholipid, is prepared under the condition of hyperthermia sterilization and decompression. Such nanometer formulation is sterile particle or powder with loose porosity. For directly intravenous use, the formulation has targeting activity, sustained release and long circulating characters. While as a solid oral product, it is fast-release, fast-effective, and improved bioavailability characters, and is readily melted in mouth. The formulation utilizes secure accessories, traditional equipments and methods, thus, it is suited to be used and manufactured widely. Also disclosed is intravenous formulation of anticancer paclitaxel, which characterized that there has no polyoxyethylenated castor oil in it. Such intravenous formulation is nonallergic so that it has higher security and efficiency compared to present commercially available paclitaxel formulations.

Description

technical field [0001] The invention relates to a solid nano-medicine and a preparation method thereof, in particular to preparing a solid nano-medicine by combining an insoluble organic drug with an amphiphilic matrix (carrier). The invention also relates to paclitaxel nano-medicine for injection and a preparation method thereof. Background technique [0002] For drugs that are poorly soluble in water, formulations prepared by conventional methods have poor and highly variable bioavailability, which affects drug efficacy. For new active compounds, formula preparations prepared by conventional methods will affect the results of preclinical screening and clinical trials, and even cause screening errors. According to reports, it is estimated that about 40% of the active substances screened by combinatorial chemistry are poorly soluble in water, which is basically the same proportion as the clinically applied poorly soluble drugs. It can be seen that "solubilization" is undou...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K47/40A61K47/24A61K9/14A61K9/127A61K9/10A61K31/337A61K31/724
CPCA61K9/0019A61K9/5138A61K9/1075A61K9/5123B82Y5/00A61K47/48969A61K31/337A61K9/5161A61K47/6951A61K9/127A61K47/24A61K47/40
Inventor 刘云清刘西瑛刘炜刘彤
Owner 刘 云清
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products